COMMUNIQUÉS West-GlobeNewswire
-
Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
23/04/2026 -
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
23/04/2026 -
AVITA Medical to Announce First Quarter 2026 Financial Results
23/04/2026 -
Chemed Reports First-Quarter 2026 Results
23/04/2026 -
Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors
23/04/2026 -
SkinnyRx GLP-1 Claims Evaluated: Review Semaglutide & Tirzepatide Weight Loss Medication Options with Clinician-Guided Care
23/04/2026 -
Denta Biome Under Investigation: Adem Naturals Chewable Dental Tablets for Oral Health Care Support
23/04/2026 -
Kane Biotech Announces Fourth Quarter and Full Year 2025 Financial Results
24/04/2026 -
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
24/04/2026 -
Coloplast A/S - Coloplast revises financial guidance for FY 2025/26 to reflect reduced growth outlook for Kerecis
23/04/2026 -
Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.
23/04/2026 -
This Alcohol Awareness Month, Oxford Treatment Center Raises Red Flag, Citing Significant Rise in Patients Seeking Help for Alcohol Addiction
23/04/2026 -
Hormify Launches Transparent, Research-Based Supplement for Hormonal Balance and Daily Wellness
23/04/2026 -
Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104
23/04/2026 -
Progyny, Inc. Announces Details for Its First Quarter 2026 Results Report
23/04/2026 -
IMAAVY® (nipocalimab)▼shows over two years of sustained disease control in a broad population with generalised myasthenia gravis (gMG)
23/04/2026 -
PridCor Therapeutics Secures Global Antiviral Portfolio, Establishing Leadership in Treatment of Long COVID and Infection-Associated Chronic Illnesses
23/04/2026 -
Chiffre d'affaires du 1er trimestre 2026
23/04/2026 -
First-quarter 2026 revenue
23/04/2026
Pages